ReviewFrontiers in medicine2026
Multimodal biomarkers and prediction models for stricturing and penetrating progression in Crohn's disease.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease can progress from non-stricturing, non-penetrating inflammation (B1) to stricturing (B2) or penetrating (B3) complications, yet risk is commonly recognized only after structural damage is established. This narrative review examines clinical, endoscopic, genomic, circulating, stool, tissue, imaging, radiomic, and computational biomarkers relevant to behavioral-progression risk and separates direct B1-to-B2 or source-defined B3 evidence from related prognostic and mechanistic evidence, while distinguishing internal penetrating from perianal fistulizing disease when source reporting permits. Structured searches of PubMed/MEDLINE, Embase, and Web of Science, supplemented by citation tracking, informed the selection of longitudinal human studies, prediction models, and mechanistic studies relevant to candidate feature selection. Ileal involvement, perianal fistulizing disease, persistent inflammatory burden, and endoscopic severity provide reproducible risk enrichment but insufficient individual-level precision. Genomic scores, plasma and stool proteins, tissue transcriptomics, shear-wave elastography, radiomics, and machine-learning models suggest potential value for multimodal risk stratification, but most lack independent external validation, calibration, transportability, and demonstrated incremental value over routinely available clinical variables. Direct prospective evidence is substantially more developed for B2 stricturing progression than for incident internal B3 penetrating progression; internal penetrating disease and perianal fistulizing disease are treated as distinct outcomes. Mechanistic studies suggest divergent fibrostenotic and tissue-destructive programs that provide biological guidance for biomarker selection. No biomarker or multimodal model identified in this review was ready to support routine biomarker-guided treatment escalation. Future studies should use well-characterized B1 baselines, prespecified structural outcomes, and prospective decision-impact testing that quantifies overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.